31 January 2025 - Boehringer Ingelheim Korea said that Jardiance (empagliflozin) 10 mg tablet, its sodium-glucose co-transporter-2 inhibitor, received expanded reimbursement for treating patients with heart failure with preserved ejection fraction (HFpEF) from 1 February 2025.

According to the new reimbursement guidelines, patients diagnosed with HFpEF—characterised by symptoms and signs of heart failure with a left ventricular ejection fraction exceeding 40%—will be eligible for insurance coverage if they have objective evidence of abnormal heart structure or function associated with left ventricular diastolic dysfunction or increased left ventricular filling pressure (NT-proBNP ≥125 pg/mL or BNP ≥35 pg/mL), or a history of emergency room visits or hospitalisations due to heart failure exacerbation within the past 12 months.

Read Korea Biomedical Review article